Research Topics
| John H GreistSummaryAffiliation: Healthcare Technology Systems Country: USA Publications
| Collaborators
|
Detail Information
Publications
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetineJohn Greist
Healthcare Technology Systems, Madison, Wisconsin 53717, USA
Clin Ther 26:1446-55. 2004..This analysis assessed the incidence, severity, onset, and duration of nausea among patients with major depressive disorder (MDD) treated with the new antidepressant duloxetine...
WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adultsJohn H Greist
Healthcare Technology Systems, Inc, Madison, Wisconsin 53717, USA
CNS Spectr 8:7-16. 2003..Further, pharmacotherapy for a minimum of 1-2 years is recommended before very gradual withdrawal may be considered...
Telephonic Remote Evaluation of Neuropsychological Deficits (TREND): longitudinal monitoring of elderly community-dwelling volunteers using touch-tone telephonesJames C Mundt
Healthcare Technology Systems, Inc, Madison, WI 53717, USA
Alzheimer Dis Assoc Disord 21:218-24. 2007..Such assessments might benefit routine clinical care and large-scale, longitudinal research in the future, but will require additional research over longer periods...
Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technologyJames C Mundt
Healthcare Technology Systems, Inc, 7617 Mineral Point Road, Ste 300, Madison, WI 53717, USA
J Psychiatr Res 44:1224-8. 2010....
An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trialsHeidi K Moore
Healthcare Technology Systems, Inc Madison, WI 53717, USA
J Clin Psychopharmacol 26:321-4. 2006....
Factors contributing to failed trials of new agents: can technology prevent some problems?John H Greist
Healthcare Technology Systems, Inc, 7617 Mineral Point, Suite 300, Madison, WI 53717, USA
J Clin Psychiatry 63:8-13. 2002..This article describes methodological factors that can confound study outcomes and discusses the potential for interactive voice response (IVR) technology to address some of these problems...
A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatologyHeidi K Moore
Healthcare Technology Systems, Inc, Madison, WI 53717, USA
J Clin Psychiatry 68:1436-40. 2007..An adolescent version of the QIDS (QIDS-A-IVR) was created using speaker-independent voice recognition technology. An informant version, QIDS-P-IVR, collects ratings from parents or other knowledgeable adults...
The Work and Social Adjustment Scale: a simple measure of impairment in functioningJames C Mundt
Healthcare Technology Systems Inc, 7617 Mineral Point Road, Suite 300, Madison, WI 53717, USA
Br J Psychiatry 180:461-4. 2002..CONCLUSIONS: The WSAS is a simple, reliable and valid measure of impaired functioning. It is a sensitive and useful outcome measure offering the potential for readily interpretable comparisons across studies and disorders...
Fluoxetine in social phobia: a double-blind, placebo-controlled pilot studyKenneth A Kobak
Dean Foundation for Health, Research and Education, Middleton, Wisconsin, USA
J Clin Psychopharmacol 22:257-62. 2002..Fluoxetine failed to separate from placebo in this trial. It is unknown whether a larger dose for longer duration would have yielded separation from placebo. A higher than usual placebo response rate was found...
Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetineHeidi K Moore
Dr Moore is with Healthcare Technology Systems, Inc, Madison, Wisconsin
Psychiatry (Edgmont) 4:30-8. 2007..This study provides new data about the usefulness of daily IVR assessments in clinical research and supports other studies regarding early symptom improvement with duloxetine...
Validation of an IVRS version of the MADRSJames C Mundt
Healthcare Technology Systems, Inc, 7617 Mineral Point Road, Madison, WI 53717, USA
J Psychiatr Res 40:243-6. 2006..Clinicians rated the severity of subjects' sadness and pessimistic thoughts lower than subjects self-report. The data obtained in this pilot study provide support for the equivalence between the clinician and IVR versions of the MADRS...
A novel interactive voice response (IVR) system for dementia screening, education, and referral: one-year summaryJames C Mundt
Healthcare Technology Systems, Inc, Madison, Wisconsin 53717, USA
Alzheimer Dis Assoc Disord 19:143-7. 2005..Overall, the 1-year results support the need for accessible and anonymous resources for individuals concerned about dementia...
Anchoring Perceptions of Clinical Change on Accurate Recollection of the Past: Memory Enhanced Retrospective Evaluation of Treatment (MERET)James C Mundt
Dr Mundt is from Healthcare Technology Systems, Inc, Madison, Wisconsin
Psychiatry (Edgmont) 4:39-45. 2007..MERET appears to be a viable method for enhancing patients' insights into the benefits of effective treatments by allowing them to use personal descriptions provided in their own words and voice...
Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a controlJohn H Greist
Healthcare Technology Systems, and the University of Wisconsin, Madison, 53717, USA
J Clin Psychiatry 63:138-45. 2002..This study compared the value of computer-guided behavior therapy value with that of clinician-guided behavior therapy and systematic relaxation as a control treatment...
The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trialTerence A Ketter
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif, USA
J Clin Psychiatry 67:400-6. 2006..This study assessed the impact of specific instructions designed to decrease risk of dermatologic reactions, including nonserious rash, during initiation of and early treatment with lamotrigine in patients with bipolar I disorder...
Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trialDavid Mataix-Cols
Department of Psychiatry, Imperial College School of Medicine, London, UK
Psychother Psychosom 71:255-62. 2002..Existing treatments need to be refined and/or new treatments developed to improve these patients' adherence and response to treatment...
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorderEric Hollander
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
J Clin Psychiatry 64:640-7. 2003....
A comparison of initial duloxetine dosing strategies in patients with major depressive disorderVirgil G Whitmyer
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
J Clin Psychiatry 68:1921-30. 2007..To compare the effects of starting doses of duloxetine taken with or without food on tolerability and efficacy in patients with major depressive disorder (MDD)...
WCA recommendations for the long-term treatment of panic disorderMark H Pollack
Division of Psychiatry, Huddinge University Hospital, Stockholm, Sweden
CNS Spectr 8:17-30. 2003..Long-term efficacy and ease of use are important considerations in treatment selection, as maintenance treatment is recommended for at least 12-24 months, and in some cases, indefinitely...
WCA recommendations for the long-term treatment of social phobiaMichael Van Ameringen
Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
CNS Spectr 8:40-52. 2003..In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months...
Cost-effectiveness of computer-aided behaviour therapy for obsessive-compulsive disorderPaul McCrone
Psychother Psychosom 76:249-50. 2007
Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technologyJudith A Dunn
Pfizer Global Research and Development, New London, Conn, USA
J Clin Psychiatry 68:525-32. 2007..The current study was designed to evaluate the validity of obtaining CSFQ data using interactive voice response (IVR) technology...
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority studyAndrew A Nierenberg
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
Curr Med Res Opin 23:401-16. 2007..The purpose of this non-inferiority study was to compare the speed of onset of antidepressant efficacy for duloxetine (a dual serotonin and norepinephrine reuptake inhibitor) and escitalopram (a selective serotonin reuptake inhibitor)...
St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind studyKenneth A Kobak
Dean Foundation for Health Research and Education, Middleton, Wisconsin 53562, USA
Int Clin Psychopharmacol 20:299-304. 2005..9%) and placebo (16.7%) (P=0.905). Only one patient from each group discontinued due to adverse events [sinus infection (St John's wort); confusion (placebo)]. The results fail to support the efficacy of St John's wort for OCD...
Immediate switching of antidepressant therapy: results from a clinical trial of duloxetineMadelaine M Wohlreich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Ann Clin Psychiatry 17:259-68. 2005..We examined the efficacy and tolerability associated with a switch from a selective serotonin reuptake inhibitor (SSRI) or venlafaxine to duloxetine...
Is it easier to find what you are looking for if you think you know what it looks like?James C Mundt
J Clin Psychopharmacol 27:121-5. 2007
